SCHEMBL2918565

SCHEMBL2918565

FC1(F)CCN(Cc2ccccc2)CC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 6/20 0.65
CYP3A4 P08684 2/20 0.65
HSD17B10 Q99714 1/20 0.65
OPRL1 P41146 1/20 0.61
ALDH1A1 P00352 2/20 0.59
CYP2C9 P11712 2/20 0.59
TSHR P16473 2/20 0.59
CYP2C19 P33261 2/20 0.59
POLB P06746 2/20 0.59
MEN1 O00255 1/20 0.59
KMT2A Q03164 1/20 0.59
HIF1A Q16665 1/20 0.59
OPRM1 P35372 1/20 0.56
MC4R P32245 1/20 0.55
CYP2D6 P10635 2/20 0.54
CCR3 P51677 1/20 0.54
TP53 P04637 1/20 0.54
CYP1A2 P05177 1/20 0.54
DRD4 P21917 1/20 0.53
LMNA P02545 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3992623 0.89 CYP3A4 (0.56) SIGMAR1CYP3A4HSD17B10OPRL1ALDH1A1
Hydrochloric Acid SCHEMBL25412712 0.87 CYP3A4 (0.54) SIGMAR1CYP3A4HSD17B10OPRL1ALDH1A1
SCHEMBL2708329 0.85 SIGMAR1 (0.61) SIGMAR1CYP3A4HSD17B10OPRL1ALDH1A1
SCHEMBL24317489 0.84 CYP3A4 (0.56) SIGMAR1CYP3A4HSD17B10OPRL1ALDH1A1
SCHEMBL3285617 0.84 RECQL (0.57) SIGMAR1TSHRCCR3DRD4
SCHEMBL2330456 0.83 OPRM1 (0.56) SIGMAR1CYP3A4HSD17B10OPRL1ALDH1A1
SCHEMBL1513357 0.83 OPRL1 (0.65) SIGMAR1CYP3A4HSD17B10OPRL1ALDH1A1
SCHEMBL4003175 0.82 SIGMAR1 (0.52) SIGMAR1CYP3A4HSD17B10OPRL1ALDH1A1
SCHEMBL1507019 0.82 HRH3 (0.52) SIGMAR1OPRL1ALDH1A1MEN1KMT2A
SCHEMBL6209937 0.82 CYP3A4 (0.57) SIGMAR1CYP3A4HSD17B10OPRL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110372572-A A kind of synthetic method of 4,4- difluoropiperdin -1- formyl chloride 苏州汉德创宏生化科技有限公司 2019-10-25 CN claimed
CN-115850156-A Method for purifying difluoride compound 上海泰坦科技股份有限公司 2023-03-28 CN disclosed
EP-3774817-B1 BCL6 INHIBITORS CANCER RESEARCH TECH LTD (GB) 2022-12-07 EP disclosed
CN-110372572-A A kind of synthetic method of 4,4- difluoropiperdin -1- formyl chloride 苏州汉德创宏生化科技有限公司 2019-10-25 CN disclosed
CN-107207532-B Nitroimidazole derivatives against tuberculosis 南京明德新药研发股份有限公司 2019-07-30 CN disclosed
US-10227362-B2 Anti-pulmonary tuberculosis nitroimidazole derivative MEDSHINE DISCOVERY INC. (CN) 2019-03-12 US disclosed
US-10227362-B2 Anti-pulmonary tuberculosis nitroimidazole derivative MEDSHINE DISCOVERY INC. (CN) 2019-03-12 US disclosed
US-20180162878-A1 ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE MEDSHINE DISCOVERY INC. (CN) 2018-06-14 US disclosed
US-20180162878-A1 ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE MEDSHINE DISCOVERY INC. (CN) 2018-06-14 US disclosed
US-20180162878-A1 ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE MEDSHINE DISCOVERY INC. (CN) 2018-06-14 US disclosed
EP-1785418-A1 PYRAZOLE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-05-16 EP disclosed
EP-1762568-A1 PYRAZOLE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-03-14 EP disclosed
EP-1698626-A1 AMIDOPYRAZOLE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed
US-20060189591-A1 Five-membered heterocyclic derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-08-24 US disclosed
US-20060128685-A1 Pyrazole derivative DAIICHI PHARMACEUTICAL CO., LTD., (JP) 2006-06-15 US disclosed
EP-1621537-A1 FIVE-MEMBERED HETEROCYCLIC DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-02-01 EP disclosed
EP-1591443-A1 PYRAZOLE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-11-02 EP disclosed
US-20050203079-A1 Compounds having affinity at 5ht2C receptor and use thereof in therapy GLAXO GROUP LIMITED 2005-09-15 US disclosed
EP-1497265-A1 COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY GLAXO GROUP LIMITED (GB) 2005-01-19 EP disclosed
WO-2003089409-A1 COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY GLAXO GROUP LIMITED (GB) 2003-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203079-A1 Compounds having affinity at 5ht2C receptor and use thereof in therapy HTR7, HTR2C, HTR3C SIGMAR1 44/4885CYP3A4 621/4885HSD17B10 810/4885
US-20060128685-A1 Pyrazole derivative PTGS1, PTGS2, PTGER1 SIGMAR1 1082/4885CYP3A4 380/4885HSD17B10 1334/4885
US-20180162878-A1 ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE NDUFV1, NDUFV2, MT-ND4 SIGMAR1 2611/4885CYP3A4 844/4885HSD17B10 999/4885
US-20060189591-A1 Five-membered heterocyclic derivative PTGS1, PTGIS, PTGS2 SIGMAR1 3899/4885CYP3A4 618/4885HSD17B10 309/4885
US-10227362-B2 Anti-pulmonary tuberculosis nitroimidazole derivative NDUFV1, NDUFV2, MT-ND4 SIGMAR1 2611/4885CYP3A4 844/4885HSD17B10 999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.